Seebri Breezhaler glycopyrronium bromide regulatory update

Vectura said Novartis submitted an NDA last quarter to FDA for NVA237 for long-term maintenance of chronic obstructive pulmonary disease (COPD). Vectura is eligible to receive a milestone payment upon...